FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 927 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR How Breast Cancer Risk Assessment Tools Work June 27, 2024 EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... March 16, 2021 Hable con su médico sobre las opciones de cirugía de mama February 13, 2024 EMA Recommends Granting a Marketing Authorisation for Decitabine / Cedazuridine August 31, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Daratumumab HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... New Survey Highlights the Role of Clinical Practice Guidelines to Improve... Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling...
